CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate...
Scottsdale, Arizona, United States and 15 other locations
is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic...
Phase 2
Scottsdale, Arizona, United States
drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy....
Phase 2
Scottsdale, Arizona, United States
+ gemcitabine + cisplatin, and oral medications of chloroquine and celecoxib help patients with previously untreated metastatic pancreatic ...
Phase 1
Scottsdale, Arizona, United States
This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic...
Phase 1, Phase 2
Scottsdale, Arizona, United States and 4 other locations
compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive ...
Phase 2
Scottsdale, Arizona, United States and 35 other locations
PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors...
Phase 1
Gilbert, Arizona, United States and 4 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Phoenix, Arizona, United States and 32 other locations
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorect ...
Phase 1, Phase 2
Gilbert, Arizona, United States of America and 7 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Phoenix, Arizona, United States and 46 other locations
Clinical trials
Research sites
Resources
Legal